Forbion builds immunity

Forbion’s fourth fund bumps up biotech allocation and continues to build newcos

With global investors’ interest in European start-ups rising, Forbion Capital Partners plans to emphasize building new companies from scratch as it invests its fourth fund. The firm hopes that by building strong relationships early in its portfolio companies’ life cycles, Forbion can avoid an increasingly competitive deal-making environment later on as

Read the full 512 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers